FDA accepts Roche ’s supplemental new drug application for Xofluza (baloxavir marboxil) for the treatment of influenza in people at high risk of complications

Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Xofluza ™ (baloxavir marboxil) as a single-dose, oral treatment for people at high risk of complications from the flu.

https://www.roche.com/investors/updates/inv-update-2019-03-06c.htm

Source: Roche Investor Update - March 6, 2019 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Influenza | New Drug Applications | Pharmaceuticals | USA Health